Bacteriophage Therapy in Tonsillitis

Acute Tonsillitis Clinical Trial

Official title:

Bacteriophage Therapy in Acute Tonsillitis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04682964
• Other study ID #: TashkentPediatricMI
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: October 2, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: December 2023
• Source: Tashkent Pediatric Medical Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa. A total of 5 ml of PCL was inhaled for 10 minutes every 5 days. The drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic E. coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Klebsiella oxytoca. The choice of this drug was based on bacteriological studies.

Description:

Comprehensive outpatient treatment was based on standard clinical guidelines, and symptomatic treatment was performed. On the first day of diagnosis, patients were prescribed complex antibacterial therapy on the basis of possible causative agents. Subsequently, antibiotic therapy was adjusted based on the results of the bacteriological examinations. A total of 67 patients received bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days. The drug causes lysis of specific bacteria including Staphylococcus, Enterococcus, Streptococcus, enteropathogenic Escherichia coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Klebsiella oxytoca. The drug is recommended for use for diseases of the ear, throat, nose, respiratory tract and lungs; inflammation of the sinuses and middle ear; tonsillitis; pharyngitis; laryngitis; tracheitis; bronchitis; pneumonia, pleurisy; and other inflammatory diseases. The choice of this drug was based on bacteriological studies.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 128
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 14 Years

Eligibility

Inclusion Criteria:

• children from 3 to 14 years old.
• children with sore throat.
• children diagnosed with acute tonsillitis.
• children diagnosed with acute respiratory infection (rhinitis, sinusitis, nasopharyngitis).
• children with the opportunity to visit the outpatient clinic.
• children with the ability to receive inhalation therapy.
• children from parents (or guardians) who have given written permission to conduct clinical and laboratory research.

Exclusion Criteria:

• children under 3 years old and over 14 years old.
• children receiving hospital treatment.
• children with acute respiratory tract diseases (bronchitis, pneumonia, pleurisy).
• children with ?hronic respiratory tract diseases (bronchitis, pneumonia).
• children who are allergic to antibiotics.
• children with cancer, immunological and hematological diseases.
• children with severe psychological illnesses (schizophrenia, mental retardation, etc.)
• children with cancer, immunological and hematological diseases.
• children with tuberculosis.

Related Conditions & MeSH terms

• Acute Tonsillitis
• Peritonsillar Abscess
• Tonsillitis

Intervention

Drug:
• Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.
Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - P?L). P?L was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.

Locations

Country	Name	City	State
Uzbekistan	Tashkent Pediatric Medical Institute	Tashkent

Sponsors (1)

Lead Sponsor	Collaborator
Tashkent Pediatric Medical Institute

Country where clinical trial is conducted

Uzbekistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical observation of sick children.	Children with clinically diagnosed acute tonsillitis are examined. The clinical study will be carried out on an outpatient basis in cooperation with the clinic of the Tashkent Pediatric Medical Institute. Prior to the study, written permission will be obtained from the parents or guardians of the children to participate in the study. Investigated: anamnesis of the child, the course of the disease, complaints of parents about the child's condition, body temperature in dynamics, visually - the state of the nasopharynx, the manifestation of clinical symptoms (sore throat, headaches, difficulty swallowing food, aphonia, and other signs) in dynamics, the functional state of internal organs (percussion, palpation and auscultation).	study of one patient - 4 weeks
Primary	Laboratory research methods.	All examined children will undergo general clinical examination and pharyngoscopy. Additionally, all patients will have tonsil swabs for bacteriological examination (bacteriological culture, n x 104/mL ) according to the standard technique. Also, swabs from the nasopharynx will be taken for viral lesions by the standard method - PCR (polymerase chain reaction). The research will be carried out in specialized laboratories.	study of one patient - 2 weeks
Primary	Experimental clinical stage. Bacteriophage therapy.	Comprehensive outpatient treatment will be based on standard clinical guidelines. Patients will be prescribed antibiotic therapy based on possible pathogens. Patients will receive bacteriophage therapy using a liquid pyobacteriophage complex (liquid pyobacteriophage complex - PCL), through nebulizer inhalation to irrigate the mucous membranes of the tonsils. Just 5 ml PCL for 10 minutes once every 5 days. Efficacy will be studied based on immunological studies.A study of cellular (class of T-lymphocytes, Inflammatory cytokines (e.g., IL-1,2,4,5,6,11,13 - U/ml) and TNF-a) and humoral ( IgA / IgM / IgG -IU/mL) immunity in children will be carried out, using (Enzyme Linked Immunosorbent Assay) ELISA which is an immunoassay, suited to the determination of antibodies in the field of infectious serology.	study of one patient - 4 weeks
Secondary	The second stage of the study (statistical).	The results will be analyzed using a statistical program based on Excel 2017 (Microsoft Office 2017). Clinical signs will be calculated as a percentage (%) incidence. We will calculate the chi-square (?2) test or Fisher's exact test (for expected values <5) to assess if certain pairs of microbes are more common than expected by chance in bacteriological examination. In addition, we will use the Kruskal-Wallis test to compare the average delay between disease onset and sample collection between samples containing one or more organisms. When evaluating immunological analyzes, characterizing the statistical significance of differences, the Student's t-test will be used with the definition of the confidence interval. The X-square test will be used to assess the frequency of identifying qualitative features. In all analyzes, P = 0.05 was considered significant.	4 weeks